Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lonapegsomatropin + navepegritide
- Development stage
- Phase 2
- Lead developer
- Ascendis Pharma
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Lonapegsomatropin + navepegritide is an investigational combination therapy developed by Ascendis Pharma for the treatment of achondroplasia in children. The regimen consists of two once-weekly subcutaneous injections: navepegritide (TransCon CNP), a prodrug of C-type natriuretic peptide (CNP), and lonapegsomatropin (TransCon hGH), a prodrug of human growth hormone (somatropin). Navepegritide targets the overactive fibroblast growth factor receptor 3 (FGFR3) pathway by activating CNP receptors, while lonapegsomatropin promotes linear growth through the growth hormone/IGF-1 axis. This dual-agent approach is designed to provide complementary effects on growth plates and skeletal development, aiming to improve annualized growth velocity and body proportionality. Clinical data from the Phase 2 COACH trial demonstrated significant improvements in growth velocity and proportionality compared to monotherapy.
- Other names
- TransCon hGH + TransCon CNP
02
Targets
GHR (Growth hormone receptor)NPR2 (C-type Natriuretic Peptide Receptor B)
Beyond the preview
Go deeper on lonapegsomatropin + navepegritide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lonapegsomatropin + navepegritide.